INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.00K | 0.00 | -- | -- | 14.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.00K | 0.00 | -- | -- | 14.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 50.00K | 0.00 | -- | -- | 14.00K |
| SG&A Expenses | 2.32M | 2.11M | 2.22M | 2.81M | 2.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.96M | 9.47M | 12.29M | 9.87M | 11.03M |
| Operating Income | -9.91M | -9.47M | -12.29M | -9.87M | -11.02M |
| Income Before Tax | -9.74M | -9.22M | -12.09M | -9.75M | -11.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.74M | -9.22M | -12.09M | -9.75M | -11.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.74M | -9.22M | -12.09M | -9.75M | -11.03M |
| EBIT | -9.91M | -9.47M | -12.29M | -9.87M | -11.02M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.43 | -0.41 | -0.60 | -0.50 | -0.61 |
| Normalized Basic EPS | -0.27 | -0.26 | -0.37 | -0.32 | -0.38 |
| EPS Diluted | -0.43 | -0.41 | -0.60 | -0.50 | -0.61 |
| Normalized Diluted EPS | -0.27 | -0.26 | -0.37 | -0.32 | -0.38 |
| Average Basic Shares Outstanding | 22.50M | 22.25M | 20.19M | 19.31M | 18.03M |
| Average Diluted Shares Outstanding | 22.50M | 22.25M | 20.19M | 19.31M | 18.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |